atenolol has been researched along with Arrhythmias, Cardiac in 87 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to dissociate the Class III effects of sotalol on QT interval and arrhythmias from those of chronic beta-receptor blockade, we compared the effects of sotalol 160 mg b." | 9.06 | A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction. ( Alexopoulos, D; Cobbe, PC; Cobbe, SM; Johnston, J; McCaie, CP; Winner, SJ, 1988) |
| "To determine the efficacy and safety of intravenous atenolol in patients with frequent and repetitive benign or potentially lethal ventricular arrhythmias, 40 patients received an open-label, single dose of 10 mg of intravenous atenolol, given in aliquots of 2." | 9.06 | Intravenous atenolol for ventricular arrhythmias. ( Morganroth, J, 1986) |
| "The effect of intravenous atenolol on ventricular arrhythmias in acute myocardial infarction was assessed in 182 patients admitted within 12 hours of the onset of chest pain." | 9.05 | Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction. ( Furze, L; Ramsdale, D; Rossi, PR; Sleight, P; Yusuf, S, 1983) |
| "The effects of atenolol on ventricular arrhythmias were evaluated in 25 men with significant ventricular ectopy." | 9.05 | Reduction of ventricular arrhythmias by atenolol. ( Heng, MK; Zimmer, I, 1985) |
| "Twenty children and adolescents treated orally with atenolol for chronic paroxysmal ventricular tachycardia (n = 10) or Long QT Syndrome (n = 10) over a 5 year period were retrospectively evaluated to ascertain the efficacy of arrhythmia suppression, the effective dosage, the cardiovascular effects, and the incidence of adverse effects." | 7.68 | Atenolol in children with ventricular arrhythmias. ( Gillette, PC; Trippel, DL, 1990) |
| "Antiarrhythmic effects of a new beta 1 selective adrenoceptor blocker, betaxolol, were examined in comparison with those of atenolol using two canine ventricular arrhythmia models (adrenaline arrhythmia and digitalis arrhythmia)." | 7.67 | Effects of betaxolol, a new beta 1 selective blocker, on canine ventricular arrhythmias. ( Akiyama, K; Hashimoto, K; Mitsuhashi, H, 1987) |
| " Adrenaline-induced arrhythmias in anaesthetized dogs respired with halothane were attenuated in 3 groups of 6 dogs by either UK-52046, 3." | 7.67 | Effects of the myocardial-selective alpha 1-adrenoceptor antagonist UK-52046 and atenolol, alone and in combination, on experimental cardiac arrhythmias in dogs. ( Harron, DW; Shanks, RG; Uprichard, AG; Wilson, R, 1988) |
| "Ventricular arrhythmia (VA) from the right ventricular outflow tract (RVOT) is a common problem." | 6.70 | Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. ( Bhuripanyo, K; Chaithiraphan, S; Kangkagate, C; Krittayaphong, R; Punlee, K, 2002) |
| " The high incidence of side-effects was probably due to the high dosage used." | 6.65 | Evaluation of the antiarrhythmic efficacy of mexiletine in patients with chronic ventricular arrhythmias. ( Van Durme, JP, 1980) |
| "In the last year, two large randomized controlled trials of metoprolol (MIAMI, almost 6,000 patients) and atenolol (ISIS 1, over 16,000 patients) given intravenously within 12 hours of the onset of acute myocardial infarction reduced mortality by about 15% in low-risk subjects." | 6.15 | Use of beta adrenoceptor blockade during and after acute myocardial infarction. ( Sleight, P, 1986) |
| "To evaluate if pretreatment with atenolol reduces frequency of ventricular arrhythmias, anesthetist interventions, or shortens procedure time." | 5.51 | Effect of preoperative administration of atenolol to dogs with pulmonic stenosis undergoing interventional procedures. ( Borgeat, K; Gomart, S; Hezzell, MJ; MacFarlane, P; Payne, JR, 2022) |
| "Atenolol can suppress PVC during exercise testing better in patients with exercise induced VA compared to those without." | 5.31 | Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease. ( Bhuripanyo, K; Chaithiraphan, S; Cheumsuk, W; Kangkagate, C; Krittayaphong, R; Punlee, K; Raungratanaamporn, O; Sriratanasathavorn, C, 2000) |
| "Ischemia-induced arrhythmias were studied during a 30 min period of occlusion of the left anterior descending (LAD) coronary artery, and 100% of control animals (n = 24) exhibited ventricular tachycardia and 63% ventricular fibrillation." | 5.27 | Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol. ( Braimbridge, MV; Hearse, DJ; Kinoshita, K; Manning, AS, 1988) |
| "The greater sensitivity of phase 1a arrhythmias to beta-blockade and the lack of a decrease in ventricular fibrillation threshold during phase 1b might indicate differences in the genesis of arrhythmias and fibrillation in phases 1a and 1b." | 5.26 | Prophylaxis of ventricular fibrillation after acute experimental coronary occlusion by chronic beta-adrenoceptor blockade with atenolol. ( Bucher, P; Meesmann, W; Menken, U; Wiegand, V, 1979) |
| "The treatment group had no cardiac arrhythmias during bronchoscopy while six of the control subjects developed arrhythmias." | 5.26 | Atenolol pretreatment in fiberoptic bronchoscopy. Effect on cardiac arrhythmias, heart rate and arterial blood pressure. ( Fassoulaki, A; Kaniaris, P; Kotsanis, S, 1980) |
| "Significant differences between pre- and posttreatment number of VPC, severity of arrhythmia, HR variables, or occurrence of syncope were not observed in dogs treated with atenolol or procainamide." | 5.10 | Comparison of the effects of four antiarrhythmic treatments for familial ventricular arrhythmias in Boxers. ( Atkins, CE; DeFrancesco, TC; Gordon, SG; Hamlin, RL; Keene, BW; Meurs, KM; Miller, MW; Moise, NS; Spier, AW; Wright, NA, 2002) |
| " To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months." | 5.09 | Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. ( Abrignani, MG; Barbagallo, M; Dominguez, LJ; Nardi, E; Novo, G; Novo, S; Strano, A, 2001) |
| "In a double-blind study, we examined the effects of early intravenous and continued oral administration of a beta-blocker (atenolol), a specific bradycardiac agent (alinidine) or placebo on left ventricular function, late coronary artery patency, infarct size, exercise capacity and incidence of arrhythmias." | 5.07 | Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. ( Brzostek, T; Collen, D; Heidbüchel, H; Janssens, L; Lesaffre, E; Mortelmans, L; Scheys, I; Van de Werf, F; Wackers, FJ; Willems, GM, 1993) |
| "In order to dissociate the Class III effects of sotalol on QT interval and arrhythmias from those of chronic beta-receptor blockade, we compared the effects of sotalol 160 mg b." | 5.06 | A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction. ( Alexopoulos, D; Cobbe, PC; Cobbe, SM; Johnston, J; McCaie, CP; Winner, SJ, 1988) |
| "To determine the efficacy and safety of intravenous atenolol in patients with frequent and repetitive benign or potentially lethal ventricular arrhythmias, 40 patients received an open-label, single dose of 10 mg of intravenous atenolol, given in aliquots of 2." | 5.06 | Intravenous atenolol for ventricular arrhythmias. ( Morganroth, J, 1986) |
| "The effects of atenolol on ventricular arrhythmias were evaluated in 25 men with significant ventricular ectopy." | 5.05 | Reduction of ventricular arrhythmias by atenolol. ( Heng, MK; Zimmer, I, 1985) |
| "The effect of intravenous atenolol on ventricular arrhythmias in acute myocardial infarction was assessed in 182 patients admitted within 12 hours of the onset of chest pain." | 5.05 | Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction. ( Furze, L; Ramsdale, D; Rossi, PR; Sleight, P; Yusuf, S, 1983) |
| "Twenty-four-hour electrocardiographic tape-recording was used to investigate the incidence of arrhythmias in patients with suspected myocardial infarction who were receiving either propranolol, atenolol, or placebo." | 5.04 | Effect of beta-blockers on arrhythmias during six weeks after suspected myocardial infarction. ( Banks, DC; Edwards, B; Fentem, PH; Hampton, JR; Roland, JM; Wilcox, RG, 1979) |
| "A series of aminoalkanolic derivatives of xanthone with high affinity for β1-adrenoceptors was evaluated for antiarrhythmic activity in the model of ischemia-reperfusion in isolated hearts, as well as in barium chloride- and adrenaline-induced model of arrhythmia." | 3.80 | Antiarrhythmic activity of some xanthone derivatives with β1-adrenoceptor affinities in rats. ( Bednarski, M; Filipek, B; Marona, H; Rapacz, A; Sapa, J; Szkaradek, N, 2014) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
| "To study a relationship between reduced heart rate variability and ventricular ectopic activity in patients with coronary artery disease and also efficiency of atenolol in suppression of ventricular arrhythmias and increase of heart rate variability." | 3.70 | [Depression of diurnal dispersion of sinus rhythm in patients after myocardial infarct]. ( Kaliuzhin, VV; Maleeva, MA; Pushnikova, EIu; Solovtsov, MA; Tepliakov, AT, 2000) |
| "Intoxication with metaproterenol, a mainly beta-2 selective agonist, was diagnosed in a dog with tachycardia, tachypnea, weakness, vomiting, and a history of exposure to the drug." | 3.68 | Metaproterenol intoxication in a dog. ( Keene, BW; Rush, JE, 1990) |
| "Twenty children and adolescents treated orally with atenolol for chronic paroxysmal ventricular tachycardia (n = 10) or Long QT Syndrome (n = 10) over a 5 year period were retrospectively evaluated to ascertain the efficacy of arrhythmia suppression, the effective dosage, the cardiovascular effects, and the incidence of adverse effects." | 3.68 | Atenolol in children with ventricular arrhythmias. ( Gillette, PC; Trippel, DL, 1990) |
| "Antiarrhythmic effects of a new beta 1 selective adrenoceptor blocker, betaxolol, were examined in comparison with those of atenolol using two canine ventricular arrhythmia models (adrenaline arrhythmia and digitalis arrhythmia)." | 3.67 | Effects of betaxolol, a new beta 1 selective blocker, on canine ventricular arrhythmias. ( Akiyama, K; Hashimoto, K; Mitsuhashi, H, 1987) |
| " Adrenaline-induced arrhythmias in anaesthetized dogs respired with halothane were attenuated in 3 groups of 6 dogs by either UK-52046, 3." | 3.67 | Effects of the myocardial-selective alpha 1-adrenoceptor antagonist UK-52046 and atenolol, alone and in combination, on experimental cardiac arrhythmias in dogs. ( Harron, DW; Shanks, RG; Uprichard, AG; Wilson, R, 1988) |
| "We studied 49 patients with type 1 diabetes (age 50." | 2.73 | Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade. ( Crea, F; Ghirlanda, G; Infusino, F; Lanza, GA; Manto, A; Musella, T; Navarese, EP; Pitocco, D; Sestito, A; Sgueglia, GA, 2007) |
| "Ventricular arrhythmia (VA) from the right ventricular outflow tract (RVOT) is a common problem." | 2.70 | Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. ( Bhuripanyo, K; Chaithiraphan, S; Kangkagate, C; Krittayaphong, R; Punlee, K, 2002) |
| "We investigated prospectively the arrhythmia incidence in 244 patients with AMI receiving alteplase and a double-blind randomized adjunctive therapy with intravenous atenolol, alinidine, or placebo." | 2.67 | Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence. ( Ballet, A; Ector, H; Heidbüchel, H; Tack, J; Van de Werf, F; Vanneste, L, 1994) |
| "Atenolol was discontinued because of adverse effects in 12 patients." | 2.66 | Atenolol for ventricular ectopy: a dose-response study. ( Fenster, PE; Goldman, S; Horwitz, LD; Lazzara, R; Marcus, FI; Morrison, D; Reynolds, D; Serokman, R; Thadani, U, 1987) |
| " The high incidence of side-effects was probably due to the high dosage used." | 2.65 | Evaluation of the antiarrhythmic efficacy of mexiletine in patients with chronic ventricular arrhythmias. ( Van Durme, JP, 1980) |
| "Atenolol is a selective beta 1-adrenoceptor antagonist with a duration of activity of at least 24 hours." | 2.38 | Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. ( Brogden, RN; Murdoch, D; Wadworth, AN, 1991) |
| "The contribution of arrhythmias is unclear." | 1.48 | Frequency of Ventricular Arrhythmias and Other Rhythm Abnormalities in Children and Young Adults With the Marfan Syndrome. ( Crosson, JE; Czosek, RJ; Lacro, RV; Love, BA; Mah, DY; McCrindle, BW; Muiño-Mosquera, L; Olson, AK; Pilcher, TA; Shah, MJ; Sleeper, LA; Tierney, ESS; Wechsler, SB; Young, LT, 2018) |
| "The vast majority of paediatric arrhythmias concerns children older than 1 year and patients with grown-up congenital heart disease." | 1.40 | How are arrhythmias managed in the paediatric population in Europe? Results of the European Heart Rhythm survey. ( Blomström-Lundqvist, C; Chen, J; Hernández-Madrid, A; Hocini, M; Pison, L; Potpara, T, 2014) |
| "Phase 2 arrhythmias appear to depend in part on a complex interaction between catecholamines and neutrophils." | 1.35 | Complex adrenergic and inflammatory mechanisms contribute to phase 2 ventricular arrhythmias in anaesthetized rats. ( Andrag, E; Clements-Jewery, H; Curtis, MJ; Hearse, DJ, 2009) |
| "Atenolol can suppress PVC during exercise testing better in patients with exercise induced VA compared to those without." | 1.31 | Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease. ( Bhuripanyo, K; Chaithiraphan, S; Cheumsuk, W; Kangkagate, C; Krittayaphong, R; Punlee, K; Raungratanaamporn, O; Sriratanasathavorn, C, 2000) |
| "The patient had no further arrhythmias on quinidine for 6 years until he inexplicably discontinued his medication and died suddenly shortly thereafter." | 1.30 | Familial sudden cardiac death associated with a terminal QRS abnormality on surface 12-lead electrocardiogram in the index case. ( Feld, GK; Finneran, W; Garg, A, 1998) |
| "Naloxone alone reduced arrhythmia incidence but to a lesser extent than U-50,488H." | 1.28 | Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusion. ( Penz, WP; Pugsley, MK; Walker, MJ; Wong, TM, 1992) |
| " Atenolol, ICI 111,581 and propranolol were given at low, medium and high doses calculated to shift dose-response curves to exogenous agonists by factors of 10-30, 100-300 and 1000-3000, respectively." | 1.28 | Mechanisms underlying the antiarrhythmic properties of beta-adrenoceptor blockade against ischaemia-induced arrhythmias in acutely prepared rats. ( Abraham, S; Beatch, GN; Paletta, MJ; Walker, MJ, 1989) |
| " The intravenous pharmacokinetic data were best described by a two-compartment model and revealed the following (mean +/- SD): total body clearance, 0." | 1.28 | Pharmacokinetics and pharmacodynamics of atenolol in children. ( Buck, ML; Gillette, PC; Krull, J; O'Neal, W; Trippel, D; Wiest, D, 1989) |
| "73 patients (89%) had ventricular extrasystoles in the 24 hour ambulatory ECG, 33 (40%) of them with an average of more than 30/h." | 1.27 | [Prevalence, therapeutic modification and prognostic significance of ventricular arrhythmias in the mitral valve prolapse syndrome]. ( Kafka, W, 1985) |
| "Ischemia-induced arrhythmias were studied during a 30 min period of occlusion of the left anterior descending (LAD) coronary artery, and 100% of control animals (n = 24) exhibited ventricular tachycardia and 63% ventricular fibrillation." | 1.27 | Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol. ( Braimbridge, MV; Hearse, DJ; Kinoshita, K; Manning, AS, 1988) |
| "Prazosin and atenolol were able to reduce significantly the incidence of ventricular fibrillation and LDH release." | 1.27 | Reoxygenation dysrhythmias in the isolated guinea-pig heart: sensitivity to prazosin, atenolol and practolol. ( Antonini, G; Franconi, F; Giotti, A; Ledda, F; Mantelli, L; Stendardi, I, 1983) |
| "The greater sensitivity of phase 1a arrhythmias to beta-blockade and the lack of a decrease in ventricular fibrillation threshold during phase 1b might indicate differences in the genesis of arrhythmias and fibrillation in phases 1a and 1b." | 1.26 | Prophylaxis of ventricular fibrillation after acute experimental coronary occlusion by chronic beta-adrenoceptor blockade with atenolol. ( Bucher, P; Meesmann, W; Menken, U; Wiegand, V, 1979) |
| "The treatment group had no cardiac arrhythmias during bronchoscopy while six of the control subjects developed arrhythmias." | 1.26 | Atenolol pretreatment in fiberoptic bronchoscopy. Effect on cardiac arrhythmias, heart rate and arterial blood pressure. ( Fassoulaki, A; Kaniaris, P; Kotsanis, S, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (42.53) | 18.7374 |
| 1990's | 14 (16.09) | 18.2507 |
| 2000's | 17 (19.54) | 29.6817 |
| 2010's | 18 (20.69) | 24.3611 |
| 2020's | 1 (1.15) | 2.80 |
| Authors | Studies |
|---|---|
| Gomart, S | 1 |
| MacFarlane, P | 1 |
| Payne, JR | 1 |
| Hezzell, MJ | 1 |
| Borgeat, K | 1 |
| Duan, L | 1 |
| Ng, A | 1 |
| Chen, W | 1 |
| Spencer, HT | 1 |
| Nguyen, J | 1 |
| Shen, AY | 1 |
| Lee, MS | 1 |
| Reno, CM | 1 |
| Skinner, A | 1 |
| Bayles, J | 1 |
| Chen, YS | 1 |
| Daphna-Iken, D | 1 |
| Fisher, SJ | 1 |
| Mah, DY | 1 |
| Sleeper, LA | 1 |
| Crosson, JE | 1 |
| Czosek, RJ | 1 |
| Love, BA | 1 |
| McCrindle, BW | 1 |
| Muiño-Mosquera, L | 1 |
| Olson, AK | 1 |
| Pilcher, TA | 1 |
| Tierney, ESS | 1 |
| Shah, MJ | 1 |
| Wechsler, SB | 1 |
| Young, LT | 1 |
| Lacro, RV | 1 |
| Reina Doreste, Y | 1 |
| Stern, JA | 1 |
| Lahmers, SM | 1 |
| Carnevali, L | 2 |
| Trombini, M | 2 |
| Porta, A | 1 |
| Montano, N | 1 |
| de Boer, SF | 1 |
| Sgoifo, A | 2 |
| Graiani, G | 1 |
| Madeddu, D | 1 |
| Quaini, F | 1 |
| Landgraf, R | 1 |
| Neumann, ID | 1 |
| Nalivaiko, E | 1 |
| Rapacz, A | 1 |
| Sapa, J | 1 |
| Bednarski, M | 1 |
| Filipek, B | 1 |
| Szkaradek, N | 1 |
| Marona, H | 1 |
| Hernández-Madrid, A | 2 |
| Hocini, M | 1 |
| Chen, J | 2 |
| Potpara, T | 2 |
| Pison, L | 2 |
| Blomström-Lundqvist, C | 2 |
| Bjerregaard Larsen, T | 1 |
| Estner, HL | 1 |
| Todd, D | 1 |
| Grazia Bongiorni, M | 1 |
| Happonen, JM | 1 |
| Blom, N | 1 |
| Celiker, A | 1 |
| Drago, F | 1 |
| Hebe, J | 1 |
| Janousek, J | 1 |
| Kornyei, L | 1 |
| Kriebel, T | 1 |
| Papagiannis, J | 1 |
| Paul, T | 1 |
| Pfammatter, JP | 1 |
| Rosenthal, E | 1 |
| Tuzcu, V | 1 |
| Jackson, BL | 1 |
| Adin, DB | 1 |
| Lehmkuhl, LB | 1 |
| Clements-Jewery, H | 1 |
| Andrag, E | 1 |
| Hearse, DJ | 2 |
| Curtis, MJ | 1 |
| Wachtell, K | 2 |
| Gerdts, E | 1 |
| Aurigemma, GP | 1 |
| Boman, K | 1 |
| Dahlöf, B | 3 |
| Nieminen, MS | 1 |
| Olsen, MH | 2 |
| Okin, PM | 2 |
| Palmieri, V | 1 |
| Rokkedal, JE | 1 |
| Devereux, RB | 2 |
| Kjeldsen, SE | 1 |
| Julius, S | 1 |
| Hille, DA | 1 |
| Edelman, JM | 2 |
| Mikesell, CE | 1 |
| Atkinson, DE | 1 |
| Rachman, BR | 1 |
| He, G | 1 |
| Hu, J | 1 |
| Li, T | 1 |
| Ma, X | 1 |
| Meng, J | 1 |
| Jia, M | 1 |
| Lu, J | 1 |
| Ohtsu, H | 1 |
| Chen, Z | 1 |
| Luo, X | 1 |
| Martinez-Sabater, H | 1 |
| Cruzado-Quevedo, J | 1 |
| Muñoz-Gimeno, L | 1 |
| Hernandez-Cascales, J | 1 |
| Workman, AJ | 1 |
| Marshall, GE | 1 |
| Rankin, AC | 1 |
| Smith, GL | 1 |
| Dempster, J | 1 |
| Meurs, KM | 1 |
| Spier, AW | 1 |
| Wright, NA | 1 |
| Atkins, CE | 1 |
| DeFrancesco, TC | 1 |
| Gordon, SG | 1 |
| Hamlin, RL | 1 |
| Keene, BW | 2 |
| Miller, MW | 1 |
| Moise, NS | 1 |
| Gomes, ME | 1 |
| Guimarães, HN | 1 |
| Ribeiro, AL | 1 |
| Aguirre, LA | 1 |
| Malmqvist, K | 1 |
| Kahan, T | 1 |
| Edner, M | 1 |
| Bergfeldt, L | 1 |
| Krittayaphong, R | 2 |
| Bhuripanyo, K | 2 |
| Punlee, K | 2 |
| Kangkagate, C | 2 |
| Chaithiraphan, S | 2 |
| Lindholm, LH | 1 |
| Ibsen, H | 1 |
| Borch-Johnsen, K | 1 |
| Snapinn, S | 1 |
| Diener, HC | 1 |
| Lobanov, AV | 1 |
| Rzhevskii, DI | 1 |
| Korshunov, VA | 1 |
| Murashev, AN | 1 |
| Kanopskiĭ, SG | 1 |
| Staritskiĭ, AG | 1 |
| Bozhko, AA | 1 |
| Khan, MN | 1 |
| Pothier, CE | 1 |
| Lauer, MS | 1 |
| Bhatt, LK | 1 |
| Nandakumar, K | 1 |
| Bodhankar, SL | 1 |
| Bansal, J | 1 |
| Piplani, P | 1 |
| Lanza, GA | 1 |
| Pitocco, D | 1 |
| Navarese, EP | 1 |
| Sestito, A | 1 |
| Sgueglia, GA | 1 |
| Manto, A | 1 |
| Infusino, F | 1 |
| Musella, T | 1 |
| Ghirlanda, G | 1 |
| Crea, F | 1 |
| Jackson, EA | 1 |
| Sullman, SA | 1 |
| Rochette, L | 1 |
| Didier, JP | 1 |
| Moreau, D | 1 |
| Bralet, J | 1 |
| Opie, LH | 1 |
| Johns, VJ | 1 |
| Rossi, PR | 1 |
| Yusuf, S | 3 |
| Ramsdale, D | 2 |
| Furze, L | 1 |
| Sleight, P | 4 |
| Pearson, M | 1 |
| Sterry, H | 1 |
| Parish, S | 1 |
| Rossi, P | 2 |
| Antonini, G | 1 |
| Franconi, F | 1 |
| Giotti, A | 1 |
| Ledda, F | 1 |
| Mantelli, L | 1 |
| Stendardi, I | 1 |
| Van Durme, JP | 1 |
| Frishman, WH | 1 |
| Djonlagić, H | 1 |
| Bos, I | 1 |
| Diederich, KW | 1 |
| Rasmussen, K | 1 |
| Andersen, K | 1 |
| Wang, H | 1 |
| Fassoulaki, A | 1 |
| Kaniaris, P | 1 |
| Kotsanis, S | 1 |
| Pimenta, J | 1 |
| Censoni, LG | 1 |
| Miranda, M | 1 |
| Heidbüchel, H | 2 |
| Tack, J | 1 |
| Vanneste, L | 1 |
| Ballet, A | 1 |
| Ector, H | 1 |
| Van de Werf, F | 2 |
| Janssens, L | 1 |
| Brzostek, T | 1 |
| Mortelmans, L | 1 |
| Wackers, FJ | 1 |
| Willems, GM | 1 |
| Lesaffre, E | 1 |
| Scheys, I | 1 |
| Collen, D | 1 |
| Saikawa, T | 1 |
| Ito, M | 1 |
| Nakagawa, M | 1 |
| Shimoyama, N | 1 |
| Hara, M | 1 |
| Yonemochi, H | 1 |
| Maeda, T | 1 |
| Inoue, T | 1 |
| Takaki, R | 1 |
| Arita, M | 1 |
| Chazan, R | 1 |
| Pertoldi, F | 1 |
| D'Orlando, L | 1 |
| Mercante, WP | 1 |
| Garg, A | 1 |
| Finneran, W | 1 |
| Feld, GK | 1 |
| Adams, JN | 1 |
| Denver, MA | 1 |
| Rae, AP | 1 |
| Fries, R | 1 |
| Heisel, A | 1 |
| Schieffer, H | 1 |
| Kaliuzhin, VV | 1 |
| Tepliakov, AT | 1 |
| Maleeva, MA | 1 |
| Pushnikova, EIu | 1 |
| Solovtsov, MA | 1 |
| Raungratanaamporn, O | 1 |
| Sriratanasathavorn, C | 1 |
| Cheumsuk, W | 1 |
| Foz, M | 1 |
| Alemany, M | 1 |
| Gausí, C | 1 |
| Novo, S | 1 |
| Abrignani, MG | 1 |
| Novo, G | 1 |
| Nardi, E | 1 |
| Dominguez, LJ | 1 |
| Strano, A | 1 |
| Barbagallo, M | 1 |
| Markos, F | 1 |
| Snow, HM | 1 |
| Kidd, C | 1 |
| Conlon, K | 1 |
| Lüderitz, B | 1 |
| Schley, G | 3 |
| Beckmann, R | 2 |
| Hengstebeck, W | 1 |
| Capucci, A | 1 |
| Verardi, P | 1 |
| Binetti, G | 1 |
| Bracchetti, D | 1 |
| Ambrosioni, E | 1 |
| Magnani, B | 1 |
| Roland, JM | 1 |
| Wilcox, RG | 1 |
| Banks, DC | 1 |
| Edwards, B | 1 |
| Fentem, PH | 1 |
| Hampton, JR | 1 |
| Menken, U | 1 |
| Wiegand, V | 1 |
| Bucher, P | 1 |
| Meesmann, W | 3 |
| Seipel, L | 1 |
| Breithardt, G | 1 |
| Döhring, HP | 1 |
| Günnewig, H | 1 |
| Abendroth, RR | 2 |
| Stephan, K | 2 |
| Hübner, H | 2 |
| Pugsley, MK | 1 |
| Penz, WP | 1 |
| Walker, MJ | 2 |
| Wong, TM | 1 |
| Wadworth, AN | 1 |
| Murdoch, D | 1 |
| Brogden, RN | 1 |
| Oppenheimer, SM | 1 |
| Cechetto, DF | 1 |
| Soria, F | 1 |
| Alegría, E | 1 |
| Valdés, M | 1 |
| García, A | 1 |
| Vicente, T | 1 |
| Castello, MJ | 1 |
| Rush, JE | 1 |
| Trippel, DL | 1 |
| Gillette, PC | 2 |
| Kafka, W | 1 |
| Cobbe, SM | 1 |
| Alexopoulos, D | 1 |
| Winner, SJ | 1 |
| McCaie, CP | 1 |
| Cobbe, PC | 1 |
| Johnston, J | 1 |
| Paletta, MJ | 1 |
| Abraham, S | 1 |
| Beatch, GN | 1 |
| Buck, ML | 1 |
| Wiest, D | 1 |
| Trippel, D | 1 |
| Krull, J | 1 |
| O'Neal, W | 1 |
| Cruickshank, JM | 1 |
| Neil-Dwyer, G | 1 |
| Hayes, Y | 1 |
| Degaute, JP | 1 |
| Kuurne, T | 1 |
| Kytta, J | 1 |
| Carruthers, ME | 1 |
| Patel, S | 1 |
| Mitsuhashi, H | 1 |
| Akiyama, K | 1 |
| Hashimoto, K | 1 |
| Uprichard, AG | 1 |
| Harron, DW | 1 |
| Wilson, R | 1 |
| Shanks, RG | 1 |
| Fogari, R | 1 |
| Zoppi, A | 1 |
| Poletti, L | 1 |
| Tettamanti, F | 1 |
| Orlandi, C | 1 |
| Rynkiewicz, A | 1 |
| Kinoshita, K | 1 |
| Braimbridge, MV | 1 |
| Manning, AS | 1 |
| Morganroth, J | 1 |
| Fenster, PE | 1 |
| Reynolds, D | 1 |
| Horwitz, LD | 1 |
| Morrison, D | 1 |
| Goldman, S | 1 |
| Thadani, U | 1 |
| Lazzara, R | 1 |
| Serokman, R | 1 |
| Marcus, FI | 1 |
| Heng, MK | 1 |
| Zimmer, I | 1 |
| Górecka, D | 1 |
| Chodosowska, E | 1 |
| Grebska, E | 1 |
| Ceci, V | 1 |
| Longo, A | 1 |
| Di Mario, F | 1 |
| Fiorella, AT | 1 |
| Aiello, P | 1 |
| Masini, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy[NCT00389168] | Phase 2/Phase 3 | 115 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Atenolol | -16.3 |
| Irbesartan | -18.8 |
Changes in common carotid artery intima-media thickness, assessed by ultrasonography. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm (Mean) |
|---|---|
| Atenolol | 0.03 |
| Irbesartan | -0.01 |
Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication. (NCT00389168)
Timeframe: Treatment period was baseline to 48 weeks
| Intervention | Participants (Number) |
|---|---|
| Atenolol | 5 |
| Irbesartan | 5 |
Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m^2). (NCT00389168)
Timeframe: Baseline and 48 weeks
| Intervention | g/m^2 (Mean) | ||
|---|---|---|---|
| 12 weeks | 24 weeks | 48 weeks | |
| Atenolol | -1 | -6 | -14 |
| Irbesartan | -9 | -14 | -26 |
Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | pmol/L (Mean) | ||
|---|---|---|---|
| Weel 12 | Week 24 | Week 48 | |
| Atenolol | -1.0 | -0.8 | -0.2 |
| Irbesartan | 3.0 | 3.3 | 10.0 |
Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| Week 12 | Week 24 | Week 48 | |
| Atenolol | 0.18 | 0.16 | 0.13 |
| Irbesartan | 0.10 | 0.04 | 0.10 |
7 reviews available for atenolol and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Prolonged QT syndrome and sedation: a case report and a review of the literature.
Topics: Arrhythmias, Cardiac; Atenolol; Child, Preschool; Conscious Sedation; Electrocardiography; Emergency | 2011 |
Comparative review of beta-blocking agents.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Atenolol; Humans; Hypertension; | 1984 |
Beta-blocking drugs for arrhythmias, hypertension, and ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Arrhythmias, Cardiac; Atenolol; Blood Pressur | 1984 |
Drug therapy: atenolol and timolol, two new systemic beta-adrenoceptor antagonists.
Topics: Arrhythmias, Cardiac; Atenolol; Coronary Disease; Humans; Hypertension; Kinetics; Propanolamines; Ti | 1982 |
[Atenolol in the treatment of patients with airway obstruction].
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Airway Resistance; Animals; Arrhythmias, Cardiac; A | 1998 |
Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
Topics: Arrhythmias, Cardiac; Atenolol; Coronary Disease; Drug Evaluation; Humans; Hypertension | 1991 |
Use of beta adrenoceptor blockade during and after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atenolol; Cardiotonic Agents; Clinical Trials as | 1986 |
23 trials available for atenolol and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Effect of preoperative administration of atenolol to dogs with pulmonic stenosis undergoing interventional procedures.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Dog Diseases; Dogs; Prospective Stu | 2022 |
Effect of atenolol on heart rate, arrhythmias, blood pressure, and dynamic left ventricular outflow tract obstruction in cats with subclinical hypertrophic cardiomyopathy.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Blood Pressure; Cardiomyopathy, Hyp | 2015 |
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Cardiovascular Diseases; Cause of Dea | 2010 |
Comparison of the effects of four antiarrhythmic treatments for familial ventricular arrhythmias in Boxers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Dog Diseases; Dogs; Drug Therapy, C | 2002 |
Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Blood Pr | 2002 |
Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atenolol; Autonomic Nervous System Diseases; C-Re | 2007 |
Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Cardiac Complexes, Premature; Clinical Trials as Topic; | 1983 |
The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction.
Topics: Arrhythmias, Cardiac; Atenolol; Clinical Trials as Topic; Creatine Kinase; Electrocardiography; Fema | 1984 |
Evaluation of the antiarrhythmic efficacy of mexiletine in patients with chronic ventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Atenolol; Chronic Disease; Clinical Trials as Topic; Disopyramide; Double-Blin | 1980 |
Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Clonidine; Double-Blind Method; Electrocardi | 1994 |
Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Cardiovascular Agents; Clonidine; Double-Blind Method; | 1993 |
Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Blood | 2001 |
Effect of beta-blockers on arrhythmias during six weeks after suspected myocardial infarction.
Topics: Arrhythmias, Cardiac; Atenolol; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; | 1979 |
[Effects of Atenolol and Propranolol on sinus node and intracardiac conduction in man (author's transl)].
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Atenolol; Bundle of His; Electrocardiography; Female; Heart | 1977 |
[The prevalence of arrhythmias and repolarization changes in patients with mild or moderate essential hypertension undergoing an exercise test. Their variations with different antihypertensive treatments].
Topics: Adult; Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Drug Evaluation; Echocardiogra | 1990 |
A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Cardiac Complexes, Premature; Clinical Trials as Topic; | 1988 |
Stress/catecholamine-induced cardiac necrosis. Reduction by beta 1-selective blockade.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atenolol; Child; Clinical Trials as Topic; Craniocere | 1988 |
Use of beta adrenoceptor blockade during and after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atenolol; Cardiotonic Agents; Clinical Trials as | 1986 |
[Effect of atenolol on the QT interval in the acute phase of myocardial infarction].
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Clinical Trials as Topic; Female; Humans; Long QT Syndr | 1988 |
Intravenous atenolol for ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Clinical Trials as Topic; Electrocardiography; Heart Ve | 1986 |
Atenolol for ventricular ectopy: a dose-response study.
Topics: Adult; Aged; Ambulatory Care; Arrhythmias, Cardiac; Atenolol; Circadian Rhythm; Dose-Response Relati | 1987 |
Reduction of ventricular arrhythmias by atenolol.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Heart Ventricles; Humans; Male; Middle Aged; Tachycardi | 1985 |
58 other studies available for atenolol and Arrhythmias, Cardiac
| Article | Year |
|---|---|
β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies.
Topics: Adrenergic beta-Antagonists; Age Factors; Arrhythmias, Cardiac; Atenolol; Body Mass Index; Californi | 2017 |
Severe hypoglycemia-induced sudden death is mediated by both cardiac arrhythmias and seizures.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Anticonvulsants; Arrhythmia | 2018 |
Frequency of Ventricular Arrhythmias and Other Rhythm Abnormalities in Children and Young Adults With the Marfan Syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Arrhythmias | 2018 |
ECG of the month. Multiple episodes of collapse in a cat.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Calcium Channel Blockers; | 2013 |
Vagal withdrawal and susceptibility to cardiac arrhythmias in rats with high trait aggressiveness.
Topics: Aggression; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Autonomic Nervous Syste | 2013 |
Low vagally-mediated heart rate variability and increased susceptibility to ventricular arrhythmias in rats bred for high anxiety.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Agonists; Animals; Anxiety; Arrhythmias, Car | 2014 |
Antiarrhythmic activity of some xanthone derivatives with β1-adrenoceptor affinities in rats.
Topics: Animals; Anti-Arrhythmia Agents; Antioxidants; Arrhythmias, Cardiac; Atenolol; Barium Compounds; Chl | 2014 |
How are arrhythmias managed in the paediatric population in Europe? Results of the European Heart Rhythm survey.
Topics: Adolescent; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Catheter Ablation; Child; Child, | 2014 |
Management of paediatric arrhythmias in Europe: authors' reply.
Topics: Arrhythmias, Cardiac; Atenolol; Catheter Ablation; Female; Flecainide; Humans; Male; Pacemaker, Arti | 2015 |
Management of paediatric arrhythmias in Europe.
Topics: Arrhythmias, Cardiac; Atenolol; Catheter Ablation; Female; Flecainide; Humans; Male; Pacemaker, Arti | 2015 |
Complex adrenergic and inflammatory mechanisms contribute to phase 2 ventricular arrhythmias in anaesthetized rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Atenolol; | 2009 |
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure; | 2010 |
What your blood pressure isn't revealing.
Topics: Adrenergic beta-Antagonists; American Heart Association; Amlodipine; Anti-Arrhythmia Agents; Antihyp | 2010 |
Arrhythmogenic effect of sympathetic histamine in mouse hearts subjected to acute ischemia.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Famotidine; Heart; Heart Rate; Hist | 2012 |
Can adenosine cause asthma-like symptoms in patients with cardiac arrhythmias receiving atenolol?
Topics: Adenosine; Adrenergic beta-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardia | 2012 |
Transient outward K+ current reduction prolongs action potentials and promotes afterdepolarisations: a dynamic-clamp study in human and rabbit cardiac atrial myocytes.
Topics: Action Potentials; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Agonists; Animals; Arrhyt | 2012 |
Does preprocessing change nonlinear measures of heart rate variability?
Topics: Adolescent; Adult; Animals; Arrhythmias, Cardiac; Atenolol; Atropine; Autonomic Nervous System; Comp | 2002 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Effect of cholinergic and adrenergic receptor blockade on arrhythmogenic activity of endothelin-1 during inhibition of nitric oxide synthesis in awake mice.
Topics: Adrenergic Antagonists; Animals; Arrhythmias, Cardiac; Atenolol; Atropine; Cholinergic Antagonists; | 2004 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Chronotropic incompetence as a predictor of death among patients with normal electrograms taking beta blockers (metoprolol or atenolol).
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atenolol; Cause of Death; Electrocardiography; Ex | 2005 |
Beta-blocking activity of PP-34, a newly synthesized aryloxypropanolamine derivative, and its cardioprotective effect against ischaemia/reperfusion injury in laboratory animals.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Atenolol; Benzylamines; Female; Guinea P | 2007 |
Role of beta-adrenoreceptor antagonism in the prevention of reperfusion ventricular arrhythmias: effects of acebutolol, atenolol, and d-propranolol on isolated working rat hearts subject to myocardial ischemia and reperfusion.
Topics: Acebutolol; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Atenolol; Cardiac Output; Co | 1984 |
Reoxygenation dysrhythmias in the isolated guinea-pig heart: sensitivity to prazosin, atenolol and practolol.
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Electrocardiography; Guinea Pigs; Heart; In Vitro Technique | 1983 |
[Sympathetic ganglionitis in the hereditary syndrome of QT prolongation (Romano-Ward syndrome); intracardiac registration of after-potentials (author's transl)].
Topics: Adult; Arrhythmias, Cardiac; Atenolol; Autonomic Nervous System Diseases; Autopsy; Electrocardiograp | 1982 |
Atrial fibrillation induced by atenolol.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Electrocardiography; Female; Human | 1982 |
Atenolol pretreatment in fiberoptic bronchoscopy. Effect on cardiac arrhythmias, heart rate and arterial blood pressure.
Topics: Aged; Arrhythmias, Cardiac; Atenolol; Blood Pressure; Bronchoscopy; Female; Fiber Optic Technology; | 1980 |
[Effect of atenolol on ST segment elevation during acute phase of transmural myocardial infarction of the anterior wall].
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Electrocardiography; Female; Hemodynamics; Humans; Male | 1980 |
Suppression of ventricular premature contractions continues after the washout of antiarrhythmic drugs.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Disopyramide; Electrocardiograp | 1993 |
Electromechanical dissociation 48 hours after atenolol overdose: usefulness of calcium chloride.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Blood P | 1998 |
Familial sudden cardiac death associated with a terminal QRS abnormality on surface 12-lead electrocardiogram in the index case.
Topics: Adolescent; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Death, Sudden, Cardiac; Electroc | 1998 |
Coronary artery spasm leading to life threatening arrhythmias.
Topics: Adrenergic beta-Antagonists; Adult; Arrhythmias, Cardiac; Atenolol; Calcium Channel Blockers; Contra | 1998 |
Influence of beta-blockers on the frequency of arrhythmia recurrences in patients with implantable cardioverter-defibrillator: an intraindividual comparison.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Arrhythmias, Cardiac; Atenolol; Defibrillators, Impla | 1998 |
[Depression of diurnal dispersion of sinus rhythm in patients after myocardial infarct].
Topics: Adult; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Circadian Rhythm; Da | 2000 |
Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Exercise Test; Female; Humans; Male; | 2000 |
[Intense muscle fatigue: an undesirable effect of beta blockers use in morbid obesity].
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atenolol; Humans; Male; Middle Aged; Muscle Fatig | 2001 |
Inhibition of neuronal nitric oxide reduces heart rate variability in the anaesthetised dog.
Topics: Acetylcholine; Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Blood Pr | 2001 |
[beta-receptor blockaders in cardiac arrhythmias].
Topics: Adrenergic beta-Antagonists; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atenolol; Bradycardia; Electro | 1978 |
[The treatment of acute cardiac dysrhythmias with atenolol (Tenormin) particularly after myocardial infarction (author's transl)].
Topics: Acute Disease; Adult; Aged; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Atrial Flutter; Car | 1978 |
[Evaluation of the electrophysiological properties of atenolol and of the combination of quinidine and atenolol in humans].
Topics: Adult; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Atrioventricular Node; Drug Evaluation; | 1979 |
Prophylaxis of ventricular fibrillation after acute experimental coronary occlusion by chronic beta-adrenoceptor blockade with atenolol.
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Dogs; Drug Administration Schedule; Heart Rate; Isoproteren | 1979 |
[Management of acute arrhythmias using atenolol in the myocardial-infarct patient].
Topics: Aged; Arrhythmias, Cardiac; Atenolol; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prop | 1978 |
[Effects of the beta-blocking agent atenolol on arrhythmias especially ventricular fibrillation and fibrillation threshold after acute experimental coronary artery occlusion (author's transl)].
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Carotid Arteries; Coronary Disease; Coronary Vessels; Dogs; | 1977 |
[Prevention of arrhythmias in acute myocardial infarct using the beta-sympatholytic ICI 66082].
Topics: Acute Disease; Animals; Arrhythmias, Cardiac; Atenolol; Dogs; Myocardial Infarction; Propanolamines | 1976 |
Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusion.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; A | 1992 |
Cardiac chronotropic organization of the rat insular cortex.
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Atropine; Cerebral Cortex; Cerebrovascular Disorders; Elect | 1990 |
Metaproterenol intoxication in a dog.
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Dog Diseases; Dogs; Echocardiography; Electrocardiography; | 1990 |
Atenolol in children with ventricular arrhythmias.
Topics: Adolescent; Arrhythmias, Cardiac; Atenolol; Cardiovascular System; Dose-Response Relationship, Drug; | 1990 |
[Prevalence, therapeutic modification and prognostic significance of ventricular arrhythmias in the mitral valve prolapse syndrome].
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atenolol; Cardiac Complexes, Premature; Electrocardio | 1985 |
Mechanisms underlying the antiarrhythmic properties of beta-adrenoceptor blockade against ischaemia-induced arrhythmias in acutely prepared rats.
Topics: Adrenergic beta-Antagonists; Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aten | 1989 |
Pharmacokinetics and pharmacodynamics of atenolol in children.
Topics: Adolescent; Arrhythmias, Cardiac; Atenolol; Child; Child, Preschool; Electrophysiology; Female; Half | 1989 |
Effects of betaxolol, a new beta 1 selective blocker, on canine ventricular arrhythmias.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Betaxo | 1987 |
Effects of the myocardial-selective alpha 1-adrenoceptor antagonist UK-52046 and atenolol, alone and in combination, on experimental cardiac arrhythmias in dogs.
Topics: Adrenergic alpha-Antagonists; Aminoquinolines; Animals; Arrhythmias, Cardiac; Atenolol; Coronary Ves | 1988 |
Chronic beta 1-blockade and control of left ventricular hypertrophy in hypertension.
Topics: Adult; Arrhythmias, Cardiac; Atenolol; Blood Pressure; Cardiomegaly; Electrocardiography; Female; Hu | 1987 |
Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol.
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Blood Pressure; Coronary Disease; Heart Rate; Male; Myocard | 1988 |
[Effect of atenolol on bronchial patency in patients with diffuse bronchial stenosis].
Topics: Adult; Aged; Arrhythmias, Cardiac; Asthma; Atenolol; Bronchial Spasm; Bronchitis; Female; Humans; Ma | 1985 |
[Comparison between atenolol and verapamil in the treatment of unstable angina].
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Arrhythmias, Cardiac; Atenolol; Drug Evaluation; Hum | 1985 |